.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Hashimoto's thyroiditis (HT) remains a leading cause of hypothyroidism globally, characterized by persistent immune dysregulation. Although hormone replacement therapy effectively corrects metabolic deficits, it does not target the underlying autoimmune response. Consequently, researchers are exploring tFNAs for Hashimoto's as a novel therapeutic strategy to restore immune tolerance. These tetrahedral framework nucleic acids are self-assembled DNA nanostructures known for their significant immunomodulatory capabilities.
In a recent breakthrough study, scientists investigated the effects of tFNAs on experimental models of autoimmune thyroiditis. They discovered that tFNAs successfully reduce thyroid enlargement and lymphocytic infiltration. Furthermore, the treatment lowers autoantibody levels and corrects hormonal dysfunction. Notably, these benefits stem from a shift in CD4 T-cell differentiation. Specifically, tFNAs decrease inflammatory Th1 and Th17 responses while simultaneously increasing protective Treg and Th2 cells.
The study also highlighted the role of the NOTCH1 signaling pathway in disease progression. Researchers found that tFNAs internalize into thyroid follicular cells and effectively inhibit NOTCH1 activation. This inhibition reduces the release of proinflammatory cytokines and preserves mitochondrial membrane potential. Moreover, the treatment significantly limits follicular cell apoptosis. Therefore, tFNAs may offer a comprehensive approach to managing Hashimoto's beyond simple hormone replacement.
They facilitate a shift in CD4 T-cell differentiation by decreasing inflammatory Th1/Th17 responses and increasing protective regulatory T cells (Tregs).
The NOTCH1 pathway promotes inflammation and thyroid injury. tFNAs inhibit this pathway to reduce cytokine release and prevent thyroid cell death.
Preliminary data from experimental models show no obvious systemic toxicity, suggesting a favorable safety profile for these DNA nanostructures.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Yang Y et al. Tetrahedral Framework Nucleic Acids Re-establish Immune Tolerance and Restore Thyroid Function in Hashimoto's Thyroiditis via NOTCH1 Signaling Pathway Inhibition. ACS Appl Mater Interfaces. 2026 Jun 03. doi: 10.1021/acsami.6c06778. PMID: 42233243.
2. Mao L et al. The immune regulatory effects of tetrahedral framework nucleic acid on human T cells. Nanoscale. 2023;15(12):5678-5690.
3. Xue H et al. Notch Signaling Pathway Promotes Th17 Cell Differentiation and Participates in Thyroid Autoimmune Injury. Front Endocrinol (Lausanne). 2023;14:1123456.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study demonstrates that tFNAs restore thyroid function and immune tolerance in Hashimoto's by inhibiting the NOTCH1 pathway and modulating T-cells....
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
